source
- Astellas secures exclusive option on Audax Biosciences preclinical IL-12 cancer drugAstellas has taken an exclusive option to license a preclinical immuno-oncology asset from Audax Biosciences, an Australian biotech company. The asset is an IL-12 based cancer therapeutic that is…
- GSK says UK restructuring will have limited impact on staff, focusing cuts on support rolesGSK executives said the company's global restructuring will only modestly affect UK staff, mainly targeting support functions at headquarters. CEO Luke Miels explained during the Q3 earnings call…